The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
| Title |
Clinical utility of nivolumab in the treatment of advanced melanoma
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, February 2016
|
| DOI | 10.2147/tcrm.s78039 |
| Pubmed ID | |
| Authors |
Ramsey Asmar, Jessica Yang, Richard D Carvajal |
| Abstract |
Melanomas are highly immunogenic tumors that evade the immune system by exploiting innate checkpoint pathways, rendering effector T-cells anergic. The immunotherapeutic approach of checkpoint inhibition can restore and invigorate endogenous antitumor T-cell responses and has become an important treatment option for patients with advanced melanoma. The CTLA-4 inhibitor ipilimumab and the PD-1 inhibitors nivolumab and pembrolizumab have been shown to induce durable responses and improve overall survival in metastatic, refractory melanoma. Optimization and validation of pretreatment biomarkers to predict response to these agents is a crucial area of ongoing research. Combination immunotherapy has recently demonstrated superior response rates compared to monotherapy; further investigation is needed to refine combinatorial strategies. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 2 | 3% |
| Korea, Republic of | 1 | 2% |
| Unknown | 55 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 17% |
| Student > Bachelor | 9 | 16% |
| Other | 7 | 12% |
| Student > Doctoral Student | 7 | 12% |
| Student > Ph. D. Student | 5 | 9% |
| Other | 6 | 10% |
| Unknown | 14 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 28% |
| Biochemistry, Genetics and Molecular Biology | 7 | 12% |
| Agricultural and Biological Sciences | 5 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Nursing and Health Professions | 2 | 3% |
| Other | 7 | 12% |
| Unknown | 18 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 June 2023.
All research outputs
#7,204,326
of 25,371,288 outputs
Outputs from Therapeutics and Clinical Risk Management
#365
of 1,323 outputs
Outputs of similar age
#108,699
of 406,420 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#10
of 57 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 406,420 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 57 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.